Brief: Amniotics Receives Positive Topline Results From Clinical Phase Ib Study With Pulmostem

Amniotics AB (publ)

25/05/2023 14:14

May 25 (Reuters) - Amniotics AB (publ)  AMNI.ST :
    * RECEIVES POSITIVE TOPLINE RESULTS FROM CLINICAL PHASE IB STUDY WITH PULMOSTEM
    * NO DOSE-LIMITING TOXICITY WERE NOTED IN FIRST OR SECOND DOSE COHORTS, WHICH WAS PRIMARY
ENDPOINT
OF STUDY
    * IN-DEPTH REVIEW OF SAFETY DATA CONFIRMS NO OTHER SAFETY SIGNALS AND REINFORCES STRONG
SAFETY
PROFILE OF PULMOSTEM

Source text for Eikon:  ID:nMFN8hN7gZ 
Further company coverage:  AMNI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))